Eyenovia Files Definitive Proxy Statement
Ticker: HYPD · Form: DEFA14A · Filed: Jan 15, 2025 · CIK: 1682639
| Field | Detail |
|---|---|
| Company | Eyenovia, INC. (HYPD) |
| Form Type | DEFA14A |
| Filed Date | Jan 15, 2025 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, regulatory-filing, shareholder-meeting
TL;DR
EYENOVIA filed its proxy statement on Jan 15, 2025 - shareholders vote soon.
AI Summary
Eyenovia, Inc. filed a Definitive Proxy Statement (DEFA14A) on January 15, 2025. This filing includes information required for their proxy statement, which is used to solicit votes from shareholders. The company is based in New York and operates in the pharmaceutical preparations sector.
Why It Matters
This filing is crucial for shareholders as it outlines important information regarding upcoming shareholder meetings and voting matters, directly impacting their ability to influence company decisions.
Risk Assessment
Risk Level: low — This is a routine regulatory filing (DEFA14A) and does not inherently present new financial risks.
Key Numbers
- 001-38365 — SEC File Number (Identifies the company's filings with the SEC.)
- 25531341 — Film Number (Internal SEC processing number for the filing.)
Key Players & Entities
- EYENOVIA, INC. (company) — Registrant
- 20250115 (date) — Filing Date
- 295 MADISON AVENUE, SUITE 2400 (address) — Business and Mail Address
- NEW YORK (location) — City of Business Address
- 10017 (zip_code) — Zip Code of Business Address
FAQ
What is the purpose of a DEFA14A filing?
A DEFA14A filing, or Definitive Proxy Statement, is used by companies to provide shareholders with information required for soliciting votes on matters to be presented at a shareholder meeting.
When was this specific DEFA14A filed by Eyenovia, Inc.?
Eyenovia, Inc. filed this DEFA14A on January 15, 2025.
What is Eyenovia, Inc.'s primary business sector?
Eyenovia, Inc. is in the Pharmaceutical Preparations sector, with SIC code 2834.
Where is Eyenovia, Inc. headquartered?
Eyenovia, Inc.'s business and mailing address is 295 Madison Avenue, Suite 2400, New York, NY 10017.
Does this filing require a fee payment?
According to the filing, no fee was required for this filing, or the fee was paid previously with preliminary materials.
Filing Stats: 1,208 words · 5 min read · ~4 pages · Grade level 14.2 · Accepted 2025-01-15 09:26:01
Key Financial Figures
- $0.0001 — and outstanding shares of common stock, $0.0001 par value per share, at a ratio of betw
Filing Documents
- tm253292d1_defa14a.htm (DEFA14A) — 23KB
- image_001.jpg (GRAPHIC) — 3KB
- 0001104659-25-003634.txt ( ) — 28KB
Forward-Looking Statements
Forward-Looking Statements Except for historical information, all the statements, expectations and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions, including the Company’s upcoming Special Meeting, approval and implementation of the proposed reverse stock split, and compliance with Nasdaq listing requirements and other potential benefits of the proposed reverse stock split. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and in some cases are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we file with the U.S. Securities and Exchange Commission. In addition, such statements could be affected by risks and uncertainties related to, among other things: the availability of sufficient financial resources to make payments on our debt obligations to Avenue Capital and to continue and complete the evaluation of our strategic alternatives, as well as the clinical development and commercialization of our products, as to which no assurance can be given; risks of our clinical trials, including, but not limited to, the costs, design, initiation and enrollment, timing, progress and results of such trials; the timing of, and our ability to submit applications for, obtaining and maintaining regulatory approvals for our products and product candidates; the potential advantages of our products, product candidate